Method for the treatment of progressive chronic interstitial lung disease
AssigneeUcb Biopharma Srl
InventorsTimothy Scott JOHNSON, Ian Trollope JAMES, Patricia J. SIME, Thomas Henry THATCHER
Life of this patent
Estimating the term…
Abstract
The present invention relates to an anti-transglutaminase type 2 antibody that blocks transamidase activity of the enzyme for use in the treatment of progressive chronic interstitial lung disease, such as Idiopathic pulmonary fibrosis (IPF).
Claims13
An anti-Transglutaminase 2 (anti-TG2) antibody for use in the treatment of a subject having progressive chronic interstitial lung disease or in the prevention of the development of progressive chronic interstitial lung disease.
An anti-Transglutaminase 2 (anti-TG2) antibody for use in the treatment of a subject having a lung fibrosis associated with COVID infection or in the prevention of the development of a lung fibrosis in a subject suffering from COVID infection.
A method for treating a subject having a progressive chronic interstitial lung disease or for the prevention of the development of a progressive chronic interstitial lung disease in a subject comprising administering a therapeutically effective amount of an anti-TG2 antibody to said subject.
A method for treating a subject having a lung fibrosis associated with COVID infection or for preventing the development a lung fibrosis in a subject suffering from COVID infection, wherein said method comprises the step of administering a therapeutically effective amount of an anti-TG2 antibody to said subject.
Use of an anti-Transglutaminase 2 (TG2) antibody for the manufacturing of a medicament for the treatment of a subject having a progressive chronic interstitial lung disease or for the prevention of the development of progressive chronic interstitial lung disease.
Use of an anti-Transglutaminase 2 (TG2) antibody for the manufacturing of a medicament for the treatment of a subject having a lung fibrosis associated with COVID infection or the prevention of the development a lung fibrosis in a subject suffering from COVID infection.
Dependencies are inferred from the claim text.